RxSight Inc. Common Stock (RXST)
Stock · NASDAQ · Health Care
$4.51as of 10/16/2026
Price chart
RXST Signal Track Record
How signals performed across all stocks →What RXST's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 38 | +4.8% | 53% | September 9, 2026 |
| Bollinger Band Breakdown | 27 | -2.2% | 41% | September 16, 2026 |
| Bollinger Band Breakout | 24 | -0.4% | 50% | August 31, 2026 |
| 200-Day Moving Average TouchActive now | 10 | +7.5% | 60% | December 16, 2025 |
| Any 20-session window (baseline) | -1.7% | 47% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About RXST
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an…
- Sector
- Health Care
- Industry
- Ophthalmic Goods
- Employees
- 461
- Website
- www.rxsight.com/
Fundamentals
- 1-day range
- $4.5$4.83
- Market cap
- $251.69M
- P/E (trailing)
- —
- P/E (forward)
- -6.60
- EPS (trailing)
- $-1.14
- Dividend yield
- —
- Beta
- 1.22
- Avg. volume
- 833.9K
How RxSight Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 25, 2026 · via SEC EDGAR / Finnhub
Forecasts
8 analyst ratings
RxSight Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- RXSTRxSight Inc. Common Stock$4.51▼ 3.43%Market cap $251.69MP/E —$4.4$13.22
- LUCYInnovative Eyewear Inc. Common Stock$0.79▼ 6.29%Market cap $6.19MP/E —$0.65$2.05
- LUCYWInnovative Eyewear Inc. Series A Warrants 8/16/27$0.0251▼ 10.36%Market cap $556.8KP/E —$0.0251$0.152
- STAASTAAR Surgical Company Common Stock$21.27▼ 4.45%Market cap $1.15BP/E 288.93$15.59$35.87
- EYENational Vision Holdings Inc. Common Stock$17.43▼ 1.30%Market cap $1.80BP/E 27.65$14.75$30.02
- WRBYWarby Parker Inc. Class A Common Stock$23.34▼ 5.08%Market cap $3.31BP/E 365.43$14.96$31
- BLCOBausch + Lomb Corporation Common Shares$16.49▼ 1.02%Market cap $5.84BP/E —$14.44$18.92
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| RXST RxSight Inc. Common Stock | $251.69M | — | $4.51 | ▼ 3.43% | $4.4$13.22 |
| LUCY Innovative Eyewear Inc. Common Stock | $6.19M | — | $0.79 | ▼ 6.29% | $0.65$2.05 |
| LUCYW Innovative Eyewear Inc. Series A Warrants 8/16/27 | $556.8K | — | $0.0251 | ▼ 10.36% | $0.0251$0.152 |
| STAA STAAR Surgical Company Common Stock | $1.15B | 288.93 | $21.27 | ▼ 4.45% | $15.59$35.87 |
| EYE National Vision Holdings Inc. Common Stock | $1.80B | 27.65 | $17.43 | ▼ 1.30% | $14.75$30.02 |
| WRBY Warby Parker Inc. Class A Common Stock | $3.31B | 365.43 | $23.34 | ▼ 5.08% | $14.96$31 |
| BLCO Bausch + Lomb Corporation Common Shares | $5.84B | — | $16.49 | ▼ 1.02% | $14.44$18.92 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- RxSight's Utilization-Growth Upside Faces Structural, Competitive Headwinds, BofA SaysYahoo · 9/23/2026
- B of A Securities Maintains Underperform on RxSight, Lowers Price Target to $5.5benzinga · 9/22/2026
- B of A Securities Maintains Underperform on RxSight, Lowers Price Target to $5.5Benzinga · 9/22/2026
Insider Activity
Insider Actions →- Eric Weinberg · September 15, 2026 · Option Exercise35.2K @ $4.34
- Eric Weinberg · September 5, 2026 · Grant59.5K
- Eric Weinberg · September 5, 2026 · Grant82.6K
- Eric Weinberg · September 5, 2026 · Grant65.7K
- Eric Weinberg · September 5, 2026 · Disposition125.0K
- Eric Weinberg · September 5, 2026 · Disposition50.0K
- Eric Weinberg · September 5, 2026 · Disposition92.2K
- Eric Weinberg · September 5, 2026 · Disposition95.0K
- Ilya Goldshleger · September 5, 2026 · Disposition92.2K
- Ilya Goldshleger · September 5, 2026 · Disposition120.0K
- Ilya Goldshleger · September 5, 2026 · Disposition98.4K
- Eric Weinberg · September 5, 2026 · Disposition87.4K
- Kurtz Ronald M MD · September 5, 2026 · Grant161.7K
- Kurtz Ronald M MD · September 5, 2026 · Grant96.1K
- Kurtz Ronald M MD · September 5, 2026 · Grant173.9K
Institutional Ownership
March 31, 2026
- Total shares held
- 37.07M
- Total value held
- $219.79M
- Institutional holders
- 158
- Unknown3.19M
- Unknown2.06M
- Unknown2.06M
- Unknown2.00M
- Unknown2.00M
- Unknown1.96M
- Unknown1.69M
- Unknown1.30M
- Unknown1.21M
- Unknown1.17M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
BofA Lowers RxSight Target to $5.5 Amid Growth Headwinds
Bank of America analysts say RxSight's potential for utilization growth is limited by structural and competitive challenges. They lowered the price target to $5.50 and keep an underperform rating. The stock is trading near its 52‑week low and close to a support level of $4.88.
BofA Lowers RxSight Target to $5.5 Amid Growth Headwinds. Bank of America analysts say RxSight's potential for utilization growth is limited by structural and competitive challenges. They lowered the price target to $5.50 and keep an underperform rating. The stock is trading near its 52‑week low and close to a support level of $4.88.